Our take on the latest news and views on data.

Relevant company news, articles, podcasts, and blog posts.

Recent Posts

Industry Trends

Clinical Trial Trends

Disease Area Trends

Recent Tweets

New England Journal of Medicine reports MANDARA Phase III data showing remission can be reached in EGPA with FASENRA treatment.

More Info: https://pryzm.ozmosi.com/product/3022 $XBI $IBB $XPH $PPH

Biogen’s ALS therapy, QALSODY® (tofersen), receives EU medicines regulatory recommendation. If approved, it will be the first therapy to treat a rare, genetic form of ALS. https://bit.ly/42SbpXH $BIIB #ALS #EU #innnovation

Dupilumab's sBLA granted FDA Priority Review for COPD with Type 2 Inflammation treatment.

More Info: https://pryzm.ozmosi.com/product/4253 $XBI $IBB $XPH $PPH

$TVTX $GNHAF CSL Vifor and Travere Therapeutics report that sparsentan has received a favorable opinion from the CHMP for treating IgA nephropathy.

More Info: https://pryzm.ozmosi.com/product/2042 $XBI $IBB $XPH $PPH

Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

600 Warren Ave,
Spring Lake, NJ 07762